Profile data is unavailable for this security.
About the company
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
- Revenue in USD (TTM)3.94m
- Net income in USD-35.89m
- Incorporated2010
- Employees23.00
- LocationCitius Pharmaceuticals Inc11 Commerce Dr Fl 1CRANFORD 07016-3501United StatesUSA
- Phone+1 (908) 967-6677
- Websitehttps://www.citiuspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioCardia Inc | 0.00 | -8.54m | 14.33m | 17.00 | -- | 5.45 | -- | -- | -1.73 | -1.73 | 0.00 | 0.2476 | 0.00 | -- | -- | 0.00 | -137.58 | -102.48 | -272.63 | -150.23 | -- | -- | -- | -1,938.01 | -- | -- | 0.00 | -- | -87.84 | -39.41 | 31.33 | -- | -47.18 | -- |
| Cocrystal Pharma Inc | 0.00 | -9.67m | 14.47m | 11.00 | -- | 1.79 | -- | -- | -0.9356 | -0.9356 | 0.00 | 0.5881 | 0.00 | -- | -- | 0.00 | -72.50 | -43.29 | -83.33 | -45.24 | -- | -- | -- | -4,873.78 | -- | -- | 0.00 | -- | -- | -- | 2.67 | -- | -43.98 | -- |
| Curis Inc | 11.65m | -36.56m | 14.83m | 33.00 | -- | -- | -- | 1.27 | -3.68 | -3.68 | 1.05 | -1.15 | 0.3323 | -- | 3.75 | 353,030.30 | -104.28 | -37.70 | -259.56 | -42.63 | 99.47 | 96.89 | -313.79 | -423.79 | -- | -- | -- | -- | 8.83 | 1.75 | 8.49 | -- | -- | -- |
| Iterum Therapeutics PLC | 390.00k | -26.96m | 15.05m | 9.00 | -- | -- | -- | 38.59 | -0.7488 | -0.7488 | 0.0107 | -0.1507 | 0.0161 | -- | 0.9512 | 43,333.33 | -111.35 | -99.44 | -231.48 | -169.64 | 94.87 | -- | -6,913.08 | -- | 1.96 | -3.43 | 1.28 | -- | -- | -- | 35.44 | -- | -39.16 | -- |
| Bioatla Inc | 0.00 | -64.71m | 15.15m | 61.00 | -- | -- | -- | -- | -1.15 | -1.15 | 0.00 | -0.5313 | 0.00 | -- | -- | 0.00 | -165.61 | -49.22 | -317.99 | -57.35 | -- | -- | -- | -3,690.17 | -- | -- | -- | -- | -- | 16.17 | 43.48 | -- | -- | -- |
| NuCana PLC (ADR) | 0.00 | -36.89m | 15.42m | 20.00 | -- | 0.4436 | -- | -- | -7,083.74 | -7,083.74 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -106.16 | -47.75 | -180.13 | -58.87 | -- | -- | -- | -- | -- | -1.59 | 0.0052 | -- | -- | -- | 31.25 | -- | -25.32 | -- |
| P3 Health Partners Inc | 1.44bn | -131.05m | 15.56m | 360.00 | -- | -- | -- | 0.0108 | -40.18 | -40.18 | 442.85 | -5.72 | 1.91 | -- | 14.07 | 4,013,756.00 | -37.78 | -49.89 | -113.11 | -253.77 | -4.05 | -1.15 | -19.83 | -46.73 | -- | -5.36 | 0.9304 | -- | 18.48 | 59.38 | -135.14 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -15.31m | 16.00m | 6.00 | -- | 1.33 | -- | -- | -2.31 | -2.31 | 0.00 | 0.7455 | 0.00 | -- | -- | 0.00 | -74.37 | -62.78 | -122.61 | -113.20 | -- | -- | -- | -- | -- | -- | 0.1037 | -- | -- | -- | -23.21 | -- | 106.17 | -- |
| Citius Pharmaceuticals Inc | 3.94m | -35.89m | 16.18m | 23.00 | -- | 0.2023 | -- | 4.10 | -2.92 | -2.92 | 0.2707 | 3.57 | 0.0302 | 0.0426 | -- | 171,483.00 | -29.76 | -29.86 | -48.25 | -35.19 | 79.99 | -- | -985.09 | -- | 0.4006 | -128.99 | 0.0106 | -- | -- | -- | 6.85 | -- | 400.55 | -- |
| IN8bio Inc | 0.00 | -20.66m | 16.60m | 18.00 | -- | 0.5915 | -- | -- | -6.48 | -6.48 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -126.22 | -79.60 | -150.81 | -91.19 | -- | -- | -- | -- | -- | -- | 0.0299 | -- | -- | -- | -1.43 | -- | -10.74 | -- |
| Regentis Biomaterials Ltd | 0.00 | -13.65m | 16.68m | -- | -- | 3.52 | -- | -- | -24.08 | -24.08 | 0.00 | 0.9159 | 0.00 | -- | -- | -- | -336.99 | -188.09 | -- | -- | -- | -- | -- | -- | -- | -1.02 | 0.2015 | -- | -- | -- | -360.91 | -- | -- | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.13m | 16.71m | 2.00 | -- | 7.09 | -- | -- | -1.18 | -1.18 | 0.00 | 0.8612 | 0.00 | -- | -- | 0.00 | -114.55 | -113.03 | -130.06 | -121.30 | -- | -- | -- | -- | -- | -1,017.39 | 0.00 | -- | -- | -- | 29.51 | -- | -- | -- |
| Apimeds Pharmaceuticals US Inc | 0.00 | -5.16m | 16.98m | 2.00 | -- | 2.08 | -- | -- | -0.4762 | -0.4762 | 0.00 | 0.6489 | 0.00 | -- | -- | 0.00 | -111.07 | -- | -138.71 | -- | -- | -- | -- | -- | -- | -162.30 | 0.0577 | -- | -- | -- | -78.73 | -- | -- | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.43m | 17.26m | 3.00 | -- | 5,002.13 | -- | -- | -0.0199 | -0.0199 | 0.00 | 0.00002 | 0.00 | -- | -- | 0.00 | -71.49 | 17.96 | -72.49 | 20.49 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -10.35 | -- | -- | -- |
| Jupiter Neurosciences Inc | 0.00 | -7.60m | 17.45m | 4.00 | -- | 302.69 | -- | -- | -0.2296 | -0.2296 | 0.00 | 0.0017 | 0.00 | -- | -- | 0.00 | -570.85 | -383.24 | -- | -- | -- | -- | -- | -902.90 | -- | -- | 0.7183 | -- | -- | -- | 49.00 | -- | -- | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -7.98m | 17.71m | 2.00 | -- | 2.25 | -- | -- | -0.1942 | -0.1942 | 0.00 | 0.1932 | 0.00 | -- | -- | 0.00 | -63.16 | -108.15 | -69.69 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.45 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Citius Pharmaceuticals Inc's reporting currency: US Dollar USD
7.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Heights Capital Management, Inc.as of 31 Dec 2025 | 799.93k | 3.85% |
| Geode Capital Management LLCas of 31 Dec 2025 | 127.53k | 0.61% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 119.72k | 0.58% |
| XTX Markets LLCas of 31 Dec 2025 | 107.12k | 0.52% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 77.76k | 0.37% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 69.85k | 0.34% |
| UBS Securities LLCas of 31 Dec 2025 | 68.17k | 0.33% |
| Two Sigma Investments LPas of 31 Dec 2025 | 60.84k | 0.29% |
| Asset Advisory Group, Inc.as of 31 Dec 2025 | 59.01k | 0.28% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2025 | 43.97k | 0.21% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
